9 Meters Biopharma's - INNT market analysis on 6th December 2020

Transaction Date	Recipient	Shares	Type	Price	Value
2nd December 2020	Israel Gp Ltd. Orbi Med	103,200	Open or private sale	$21.60	$2,229,120.00
27th November 2020	John Temperato	203,667	Grant/award etc.	$0.00
9th November 2020	Lorin K Johnson	4,262	Exercise of in-the-money or at-the-money derivatives securities (usually options)	$4.00	$17,048.00
30th October 2020	Israel Gp Ltd. Orbi Med	1,943,734	Other acquisition or disposition	$0.00
30th October 2020	Nissim Darvish	1,943,734	Other acquisition or disposition	$0.00
30th October 2020	Mark A Sirgo	4,513	Other acquisition or disposition	$0.00
30th October 2020	John Temperato	4,513	Other acquisition or disposition	$0.00
11th September 2020	Mark A Sirgo	21,485	Open or private purchase	$0.65	$14,003.92
11th September 2020	Mark A Sirgo	77,000	Open or private purchase	$0.68	$52,360.00
10th September 2020	Mark A Sirgo	50,000	Open or private purchase	$0.60	$30,000.00

9 Meters Biopharma

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Innovate Biopharmaceuticals, Inc. is a clinical-stage biopharm Pharmaceutical company. The company is founded by Jay P. Madan and Kendyle Woodard in 2012.

Ticker: INNT

Sector: Healthcare

Industry: Biotechnology

SEC Central Index Key (CIK): 1551986

Employees: 8

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis